Abstract The Beaumont Behavioural Inventory (BBI) is a behavioural proxy report for the assessment of behavioural changes in ALS. This tool has been validated against the FrSBe, a non-ALS-specific behavioural assessment, and further comparison of the BBI against a disease-specific tool was considered. This study cross-validates the BBI against the ALS-FTD-Q. Sixty ALS patients, 8% also meeting criteria for FTD, were recruited. All patients were evaluated using the BBI and the ALS-FTD-Q, completed by a carer. Correlational analysis was performed to assess construct validity. Precision, sensitivity, specificity, and overall accuracy of the BBI when compared to the ALS-FTD-Q, were obtained. The mean score of the whole sample on the BBI was 11.45 ± 13.06. ALS-FTD patients scored significantly higher than non-demented ALS patients (31.6 ± 14.64, 9.62 ± 11.38; p \ 0.0001). A significant large positive correlation between the BBI and the ALS-FTD-Q was observed (r = 0.807, p \ 0.0001), and no significant correlations between the BBI and other clinical/demographic characteristics indicate good convergent and discriminant validity, respectively. 72% of overall concordance was observed. Precision, sensitivity, and specificity for the classification of severely impaired patients were adequate. However, lower concordance in the classification of mild behavioural changes was observed, with higher sensitivity using the BBI, most likely secondary to BBI items which endorsed behavioural aspects not measured by the ALS-FTD-Q. Good construct validity has been further confirmed when the BBI is compared to an ALS-specific tool. Furthermore, the BBI is a more comprehensive behavioural assessment for ALS, as it measures the whole behavioural spectrum in this condition.
Introduction
The notion of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) as two extremes of the same disease continuum [1] has offered a better understanding of the clinical overlap between these conditions. Behaviour changes are a frequent and significant presentation in ALS, and behavioural assessments are fundamental in routine neuropsychological evaluations in this population. To this end, the Beaumont Behavioural Inventory (BBI) [2] was developed. The BBI is a 41-item, self-explanatory, proxy-report behavioural assessment, specifically developed for use in ALS patients as it considers the whole spectrum of behavioural changes that can occur in this condition. Moreover, the BBI accounts for the confounding effects of motor dysfunction on behaviour. The BBI has demonstrated high internal consistency (Cronbach's alpha = 0.906) [3] , and adequate convergent and discriminant validity (refer to [2] for tool development and validation details). The BBI cut-off scores (C7 for mild behaviour changes and C23 for severe behaviour changes) have high sensitivity and specificity, when validated against another behavioural tool, the Frontal System Behaviour Scale (FrSBe) [4] . Nonetheless, the use of the FrSBe as the gold standard to capture behavioural deficits in ALS raises concerns regarding the possibility of overestimating the presence of such deficits, as this tool does not correct for the effects of motor involvement in behaviour. Thus, there is a need to further compare the BBI against another ALS-specific tool that controls for such confounding effects.
Here, we cross-validate the BBI against the ALS-FTD-Q [5] , with the aim of comparing these two disease-specific measures and explore their ability to capture the entire spectrum of behavioural changes in ALS.
Methods

Participants and assessment procedures
Based on EMGO? guidelines for the validation of measurement tools [6] , 60 consecutive patients fulfilling El Escorial criteria [7] for the diagnosis of ALS and attending the MND National Clinic in Beaumont Hospital were recruited. Exclusion criteria included history of neurological, psychiatric, or medical conditions other than ALS that can cause cognitive and behavioural changes. Five participants (8%) from this cohort also met criteria for the diagnosis of behavioural variant FTD [8] .
All patients meeting inclusion criteria were assessed in one of their clinic visits. Thus, the main carer accompanying the patient was asked to complete the BBI and the ALS-FTD-Q. Carers completing the forms included spouses (58%), children (30%), siblings (7%), and other (5%; granddaughter, friend, and brother-in-law). The revised ALS functional rating scale (ALSFRS-R) [9] was also completed in a subset of patients (n = 20) to assess disease severity. Demographic and clinical characteristics were acquired from the Irish ALS register [10] .
This study is part of a broader population-based study of cognition in ALS, for which full approval from the Beaumont Hospital Ethics Committee was attained.
Statistical analyses
The Bland-Altman measure of agreement was used to determine the appropriateness of sample size [11] . Assuming a sample size n = 60, the formula for the confidence interval for the 95% limits of agreement was implemented: CI ¼ AE1:96 ffiffi 3 n q s. Assumption of normality of individual differences between ALS-FTD-Q and BBI was calculated using the formula: d AE 1:96s. Descriptive statistics are presented in terms of means and standard deviations (sd) for quantitative data, and in number of cases (n) and percentage (%) for count data. All group comparisons were performed using non-parametric methods (independent Samples Mann-Whitney U Test), as assumption of normal distribution for all samples could not be assumed.
Correlational analysis was performed between the BBI and the ALS-FTD-Q to assess construct validity (convergent validity), and between the BBI and other clinical and demographic components (age, years of education, age at onset, age at diagnosis, diagnostic delay, and ALSFRS-R) to assess discriminant validity.
Precision, sensitivity, and specificity of the BBI in comparison to the ALS-FTD-Q were calculated. Accuracy or overall correctness was also obtained. To do so, the following formulae were applied:
• Precision or consistency between tests = true positives/ (true positives ? false positives).
• Sensitivity or true-positive rate = true positives/(true positives ? false negatives).
• Specificity or true-negative rate = true negatives/(true negatives ? false positives).
• Accuracy or correct classifications = true positives/total observations.
Behavioural changes on the BBI are assessed on a 3-point rating scale (0 no changes, 1 mild, 2 moderate, and 3 severe), and the score ranges from 0 to 123. On the other hand, the presence of behavioural changes on the ALS-FTD-Q is graded on a 4-point scale (0 completely disagree/ never, 1 largely disagree/sometimes, 3 largely agree/often, and 4 completely agree/always), and the maximum score is 100. Thus, on both measures, the higher the score, the higher the presence of behavioural change. For the ALS-FTD-Q, the cutoff for mild disturbances is considered at C22, and for severe disturbances, at C29 [5] . The BBI cutoffs are C7 for mild changes and C23 for severe changes [2] .
IBM statistical package for the social sciences (SPSS) 22.0 was used for analyses.
Results
Sample size adequacy was assessed by calculating the limits of agreement, as per Bland and Altman [11] . A normal distribution within individual's measurements differences was assumed:
d AE 1:96s ¼ À15:435 and 17:565 (see Fig. 1 ). 95% limits of agreement using a sample size of 60 participants were as follows: CI ¼ AE1:96 ffiffiffi ffi Thus, a sample size of 60 gives a CI of ±0.44 * s, which is a low limit of agreement, robust enough to detect differences between measures. Table 1 summarizes demographic and clinical characteristics of the sample.
Considering that the ALSFRS-R was available only for a proportion of the total sample, comparability of the subset of patients that had an ALSFRS-R (n = 20), and the subset that had not (n = 40) was examined. No significant differences between the two subsamples were observed in terms of demographic or clinic characteristics: (age: ALSFRS-R = 66.80 ± 8. Regarding behavioural measures, the mean score for the BBI was 11.45 ± 13.06, and 14.35 ± 13.43 for the ALS-FTD-Q. When the sample was divided between patients meeting criteria for the diagnosis of ALS-FTD and ALS patients without dementia, ALS-FTD patients scored significantly higher on both the BBI (ALS-FTD = 31.6 ± 14.64, ALS = 9.62 ± 11.38; p \ 0.0001) and the ALS-FTD-Q (ALS-FTD = 34.8 ± 10.33, ALS = 12.49 ± 12.12; p = 0.002).
Group comparisons on behavioural measures between patients that had an ALSFRS-R (n = 20) and patients for whom this was not available (n = 40) were also performed. No significant difference was observed on the ALS-FTD-Q (ALSFRS-R = 18.20 ± 14.42, ALSFRS-R = 12.43 ± 12.65; p = 0.074), although a significant difference was found on the BBI (ALSFRS-R = 16.25 ± 14.29, ALSFRS-R = 9.05 ± 11.88; p = 0.040). Considering that the majority of ALS-FTD participants are included in the group that had an ALSFRS-R performed, and this is likely to have had an effect on these results, this analysis was carried out excluding all ALS-FTD cases. Results indicated that no significant difference existed on the BBI between patients who had ALSFRS-R and patients who did not (ALSFRS-R = 13.64 ± 12.34, ALSFRS-R = 7.82 ± 10.61; p = 0.076).
Regarding correlational analysis, a significant large positive correlation was observed between the BBI and the ALS-FTD-Q total scores (r = 0.807, p \ 0.0001). No significant associations were observed between the BBI and most demographic and clinical measures: age (r = -0.074, p = 0.576), education (r = -0.077, p = 0.558), age at onset (r = -0.100, p = 0.450), age at diagnosis (r = -0.066, p = 0.615), and ALSFRS-R (r = -0.014, p = 0.954); or between most clinical/demographic characteristics and the ALS-FTD-Q: age (r = -0.175, p = 0.181), education (r = -0.153, Fig. 1 Bland-Altman Plot of within individual's measurements differences Cross-tabulated data for the BBI and ALS-FTD-Q are presented in Table 2 . Precision, sensitivity, and specificity for each diagnostic category, as well as overall accuracy are presented in Table 3 .
Further exploratory analysis was performed. In cases where the BBI seemed to overestimate the behavioural categorization when compared to the ALS-FTD-Q, items more frequently endorsed within this sub-cohort (n = 17) were investigated. Items for which some degree of change was indicated by more than half of the subsample ([8 participants) were considered as frequently endorsed.
Two items from the BBI were endorsed by most caregivers in this subset of the sample: a social cognitive item ('diminished social interest') and an apathy item ('loss of motivation for previous interests'). Within the behaviour category loss of sympathy or empathy from the revised diagnostic criteria for bvFTD [8] , the ALS-FTD-Q assesses the item 'diminished responsiveness to other people's needs and feelings', but it does not assess 'general decline in social engagement', which is, indeed, assessed by the BBI. In terms of apathy, the ALS-FTD-Q includes two items: 'less interest in surroundings' and 'display of more withdrawn behaviour'. The BBI, on the other hand, includes an apathy item which is more specific to loss of interest in the previous rewarding activities. To assess reliability of apathy measurement within the two scales, correlational analysis was performed between the apathy items on the ALS-FTD-Q and the highly endorsed apathy item on the BBI ('loss of interest in previous interests'). Spearman's rank correlation coefficients were calculated, and no significant findings were observed: 'less interest in surroundings' (q = 0.252; p = 0.330); 'display of more withdrawn behaviour' (q = 0.285; p = 0.267).
Other behavioural aspects that were frequently endorsed (by 7/8 participants) by this sub-cohort of patients who were classified as abnormal on the BBI but as normal on the ALS-FTD-Q (n = 17) included 'distractibility', 'inappropriate emotional display', 'increased sensitivity to sensations such as touch, noise, heat, cold, taste, or pain', and 'increased occurrence of grammatical mistakes'. Although decreased concentration and impaired emotional stability are assessed by the ALS-FTD-Q, this does not assess altered responses to sensory stimuli or cognitive changes related to language.
Discussion
The BBI, an ALS-specific behavioural scale, has been further validated against another disease-specific behavioural instrument, the ALS-FTD-Q. BBI scores highly correlated with ALS-FTD-Q scores, but were independent of other clinical and demographic measures such as age, years of education, age at onset, age at diagnosis, and ALSFRS-R. Thus, the current cross-validation of the BBI has confirmed adequate convergent and discriminant validity. Nonetheless, when performing correlational analysis, a significant positive medium correlation between the degree of behavioural change on both the BBI and the ALS-FTD-Q, and diagnostic delay was observed. A possible explanation for this observation is that three out of the five ALS-FTD patients in this sample experienced cognitive/behavioural changes before or at the same time as the motor symptoms, which would have prompted a diagnosis of FTD, and delayed the diagnosis of ALS. This proposition was supported by the longer diagnostic delay of the ALS-FTD group, compared to the ALS group. Therefore, with this hypothesis in mind, correlational analysis was repeated excluding the ALS-FTD sub-cohort, and no significant correlations between behavioural changes and diagnostic delay were further observed.
The original BBI validation established a cutoff of C7 for mild behavioural changes (88% sensitivity and 79% specificity), and C23 for severe behavioural changes (90% sensitivity and 96% specificity). Considering these cutoffs, 47% of the ALS sample presented with behavioural changes. When compared to the ALS-FTD-Q, classification assessment indicated that a cutoff of C23 on the BBI is adequate for the diagnosis of severe behavioural changes (precision = 67; sensitivity = 100; specificity = 92). A cutoff of C7 showed limited accurateness in diagnosing mild behavioural changes (precision = 19). However, further investigation of items endorsed by 'over categorized' participants on the BBI showed that most of these items assess behavioural aspects not measured by the ALS-FTD-Q. Among them, a general decline in social engagement, a loss of interest in previously rewarding interests, higher sensitivity to sensory stimuli, and the presence of more grammatical mistakes outstand. Thus, significant behavioural aspects in ALS such as diminished social interest or an altered response to sensory stimuli are not measured by the ALS-FTD-Q. Moreover, the ALS-FTD-Q incorporates cognitive items that focus solely on executive function, and do not consider language changes. Finally, although the ALS-FTD-Q measures apathy, correlations between apathy items on the ALS-FTD-Q and the BBI were not significant, indicating that such items assess different aspects of apathy, and the BBI item 'loss of motivation for the previous interests' seems to be more sensitive to capture changes. In conclusion, cross-validation of the BBI against the ALS-FTD-Q has shown that the BBI is more sensitive to mild behavioural changes in ALS, as it assesses the entire behavioural spectrum observed in this condition. These data confirm that the BBI is a robust and psychometrically sound tool for the assessment of behavioural changes in ALS. Further cross-sectional and longitudinal populationbased studies with large incident samples are needed to confirm the prevalence of behavioural changes in ALS using this new behavioural measure.
